264 related articles for article (PubMed ID: 23587947)
1. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Elefanti A; Mouton JW; Verweij PE; Tsakris A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Oct; 57(10):4656-63. PubMed ID: 23856768
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
4. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.
Spreghini E; Orlando F; Santinelli A; Pisa E; Loretelli C; Manso E; Milici ME; Scalise G; Barchiesi F
Antimicrob Agents Chemother; 2009 Sep; 53(9):4035-9. PubMed ID: 19596890
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions.
Perkhofer S; Jost D; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2008 May; 52(5):1873-5. PubMed ID: 18347112
[TBL] [Abstract][Full Text] [Related]
7. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Seyedmousavi S; Meletiadis J; Melchers WJ; Rijs AJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2013 Feb; 57(2):796-803. PubMed ID: 23183435
[TBL] [Abstract][Full Text] [Related]
9. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
[TBL] [Abstract][Full Text] [Related]
10. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Clemons KV; Schwartz JA; Stevens DA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4439-49. PubMed ID: 22687510
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, and Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungus Sarocladium (Acremonium) kiliense.
Fernández-Silva F; Capilla J; Mayayo E; Sutton DA; Hernández P; Guarro J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6265-9. PubMed ID: 24100490
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
Olson JA; George A; Constable D; Smith P; Proffitt RT; Adler-Moore JP
Antimicrob Agents Chemother; 2010 Sep; 54(9):3884-94. PubMed ID: 20606065
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of in vitro pharmacodynamic properties of amphotericin B, voriconazole and caspofungin against A. fumigatus isolates by the conventional and colorimetric time-kill assays.
Kiraz N; Oz Y; Dag I
Med Mycol; 2011 Aug; 49(6):594-601. PubMed ID: 21299374
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibility of Saccharomyces cerevisiae and therapy in a murine model of disseminated infection.
Pérez-Cantero A; Thomson P; Paredes K; Guarro J; Capilla J
Rev Iberoam Micol; 2019; 36(1):37-40. PubMed ID: 30765275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
